Vertex to acquire T1D therapeutics maker ViaCyte for $320m
The agreement follows the US Food and Drug Administration (FDA) lifting the clinical hold on the Phase 1/2…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Jul 22
The agreement follows the US Food and Drug Administration (FDA) lifting the clinical hold on the Phase 1/2…
07 Jul 22
The three companies formed a joint venture, dubbed Aurobac Therapeutics, which will develop both next-generation antimicrobials and diagnostics…
06 Jul 22
In addition, several hundred start-ups or scale-ups (which have entered the next phase of development) will participate as…
05 Jul 22
Impact includes insulin, glibenclamide and oxaliplatin, and other medicines to fight a wide range of areas including diabetes,…
27 Jun 22
The investment will be implemented in two stages where the first stage will focus on developing vaccines, plasma,…
23 Jun 22
The FDA approval was based on data from seven randomised, double-blind clinical studies that evaluated Vaxneuvance in infants,…
20 Jun 22
The US agency expanded EUAs for the Pfizer-BioNTech and Moderna Covid-19 vaccines to include their use in children…
19 May 22
The US Centres for Disease Control and Prevention (CDC) has confirmed the first monkeypox infection, after conducting a…
06 May 22
MR-004 is an investigational prescription digital therapeutic that leverages a combination of sensors, software, and music based on…
28 Apr 22
The turnkey drug discovery solution leverages Valo’s AI-powered Opal Computational Platform and Charles River’s preclinical expertise